Sensei Biotherapeutics (NASDAQ:FTH) CFO Buys $181,089.79 in Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson bought 8,183 shares of the company’s stock in a transaction on Monday, June 22nd. The stock was bought at an average cost of $22.13 per share, for a total transaction of $181,089.79. Following the completion of the acquisition, the chief financial officer directly owned 8,183 shares of the company’s stock, valued at approximately $181,089.79. This represents a ? increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Sensei Biotherapeutics Stock Down 7.3%

FTH opened at $22.87 on Friday. The stock has a market capitalization of $30.69 million, a PE ratio of -0.16 and a beta of -0.25. Sensei Biotherapeutics, Inc. has a 1 year low of $6.32 and a 1 year high of $36.76.

Wall Street Analyst Weigh In

FTH has been the subject of several recent analyst reports. BTIG Research raised shares of Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, June 11th. Robert W. Baird assumed coverage on Sensei Biotherapeutics in a research report on Friday. They issued an “outperform” rating and a $57.00 price objective on the stock. HC Wainwright started coverage on Sensei Biotherapeutics in a research note on Monday, June 22nd. They set a “buy” rating and a $60.00 target price on the stock. Finally, Weiss Ratings initiated coverage on Sensei Biotherapeutics in a report on Wednesday, June 17th. They issued a “sell (d-)” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Sensei Biotherapeutics currently has an average rating of “Moderate Buy” and an average price target of $58.50.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.